Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluation of the Safety and Efficacy of BAFFR CAR-T Therapy in Clinical Studies for Recurrent/Refractory B Cell Tumors.

NCT07196111 is registered in ClinicalTrials.gov with Guangzhou Bio-gene Technology Co., Ltd as lead sponsor.

NCT NCT07196111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07196111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluation of the Safety and Efficacy of BAFFR CAR-T Therapy in Clinical Studies for Recurrent/Refractory B Cell Tumors.
Lead sponsor
Guangzhou Bio-gene Technology Co., Ltd
Phase
Phase 1
Overall status
Withdrawn
Start date
October 10, 2025
Completion date
December 9, 2028
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia/lymphoma